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brain metastases (BMs) with only modest improvement of 
overall survival. 
Materials and Methods: To evaluate the impact of PCI on 
survival we reviewed 179 LD SCLC patients treated with 
definitive chemoradiotherapy (CRT) in the concurrent or 
sequential setting. PCI was applied in the partial and 
complete responders exclusively provided contrast-enhanced 
cranial magnetic resonance imaging (cMRI) before and after 
primary treatment showed no signs of occult BMs. Correlation 
between PCI and time to progression (TTP) as well as overall 
survival (OS) was analysed. Kaplan-Meier analysis, uni- and 
multivariate Cox regression were used to describe survival 
within subgroups defined by treatment response and 
application of PCI. 
 
Results: Concurrent and sequential chemoradiotherapy CRT 
was applied in 71 (40%) and 108 (60%) patients, respectively. 
In 58 (32%) patients metachronous BMs were detected. PCI 
was applied in 71 (39%) patients. 15 patients developed BMs 
after PCI. Median TTP and OS in responders treated with PCI 
were 812 and 801 compared to 355 (range: 284 - 456) (p < 
0.0001, log-rank test) and 385 (range: 318 – 452) (p < 0.0001, 
log-rank test) days in the rest of the patient cohort. In 
multivariate analysis, application of PCI in treatment 
responders comprehensively staged with cMRI was a variable 
that significantly correlated with TTP (HR 2.16 CI HR 1.37-
3.42, p < 0.001) and OS (HR 1.89 CI HR 1.37-2.63, p < 0.0001) 
after adjustment of other patient- and treatment-related 
factors. 
 
Conclusion: In this LD SCLC patient cohort comprehensively 
staged with cMRI, achievement of maximum treatment 
response and application of PCI significantly affects time to 
progression and overall survival. 
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Purpose or Objective: Preoperative chemoradiotherapy 
(CRT) has been established as the standard treatment for T3-
4 rectal cancers. In a phase II trial, we reported limited 
toxicity and excellent local control using image-guided and 
intensity-modulated RT (IG-IMRT) with a simultaneous 
integrated boost (RTSIB) instead of concomitant 
chemotherapy. The present multicentric randomized trial 
compares this strategy to CRT. In addition, the neutrophil-
to-lymphocyte ratio (NLR) and C-reactive protein (CRP) were 
examined as a prognostic immunoscore in a subset of 
patients. 
 
Materials and Methods: cT3-4 rectal cancer patients were 
randomly assigned to receive either preoperative IG-IMRT 
46Gy/23 fractions plus capecitabine 825 mg/m2 twice daily 
(CRT-arm) or IG- IMRT 46Gy/23 fractions with a SIB to the 
rectal tumor up to a total dose of 55.2 Gy (RTSIB- arm). 
Metabolic tumor activity reduction, by measuring the 
percentage of SUVmax difference (Response Index = RI) on 
sequential 18-fluorodeoxyglucose positron emission 
tomography (FDG-PET), was the primary endpoint. We 
assessed whether RTSIB was non-inferior to CRT with a non-
inferiority margin of -10% for RI. 
 
Results: A total of 174 patients were randomly assigned to 
the CRT-arm (n=89) or RTSIB- arm (n=85). A consort flow 
diagram is presented in Figure 1. The RI difference between 
RTSIB and CRT was -2.9% (95% CI, -10.1% to 4.3%). The ypCR 
rate was 24% with CRT compared to 14% with RTSIB (p=0.13). 
There was no significant difference in sphincter preservation 
(75% vs 68%, p=0.29). The R0 resection rate was 98% in the 
CRT-arm and 97% in the RTSIB-arm. Acute grade 3 toxicity 
was 6% and 4% in the CRT- and RTSIB-arm, respectively. A 
detailed analyses of early adverse events is shown in Table 1. 
The highest quartiles of NLR and CRP identified high-risk 
patients in terms of disease free and overall survival. 
 
 
 
 
Conclusion: Preoperative CRT is well tolerated when IG-IMRT 
is used. RTSIB represents an attractive alternative to CRT for 
patients with a contra-indication for chemotherapy. The 
immunological landscape of colorectal cancer shapes novel 
possibilities for risk assessment. 
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Purpose or Objective: PROS-IT is a national, multicenter, 
observational prospective cohort study on prostate cancer 
(PCa) coordinated by the Italian National Research Council, 
aiming at a comprehensive evaluation of the impact of PCa 
and its treatment in an unselected aging population. Present 
analysis evaluates the frequencies of the different 
comorbidities and medications in the study population at 
diagnosis. 
 
Materials and Methods: 1684 patients (pts) consecutively 
enrolled 9/2014 to 7/2015 in 96 Institutions were submitted 
to a structured interview to record comorbidities and drugs 
assumption. The severity of comorbidities was measured with 
the Cumulative Illness Rating Scale (CIRS). Quality of life 
(QoL) was assessed by the SF-12 questionnaire (PCS = Physical 
and MCS = Mental Component Summary) and through the 
Italian UCLA P Ca Index (Function/Bother: UF,UB=Urinary , 
SF,SB=Sexual , BF,BB=Bowel ). Differences between pts 
enrolled by Urology [URO] and Radiation Oncology Centers 
[RO] were assessed with logistic regression and/or general 
linear models. 
 
Results: 996/1684 (59.1%) and 688/1684 (40.9%) pts were 
respectively enrolled by URO and RO Centers; CIRS data were 
available for 1637 pts. RO pts were older (average 71.9 yrs vs 
66.4, p<0.0001), with more advanced T category (T1 cases: 
38% vs 54.6%, p<0.0001). 445/1684 (27.2%) pts suffered from 
vascular, lymphatic or hematopoietic moderate, severe or 
very severe (MSVS) diseases; 304/1684 (18.6%) from heart 
MSVS disease; 231/1684 (14.2%) had gastro-intestinal 
problems; 163/1684 (10%) neurological diseases. The 
presence of ≥3 MSVS comorbidities had a significant negative 
impact on PCS, MCS, UB, BF and BB, SF if compared to 0-2 
MVSV comorbidities (p<0.001).Diabetes was more frequent in 
RO pts than in URO ones (18.4% vs.11.4%, p=0.0082); MSVS 
gastrointestinal disease (18.8% vs. 7.5%), abdominal hernia 
(5.7% vs. 4.8%), and neurological disease (11.4% vs. 7.9%) in 
URO pts. 74.3% of the pts use drugs for vascular disease, 
36.7% antithrombotic agents, 34.2% digestive drugs, 14.4% 
hypoglycemic drugs, 31.6% drugs for low urinary tract 
symptoms. A significant difference between URO and RO 
populations in the use of antithrombotic agents was evident: 
32.5% URO vs. 44% RO (p=0.0377). 
 
Conclusion: This study shows that number and severity of 
comorbidities had a negative impact on QoL at the time of 
diagnosis of PCa. Moreover, men enrolled in URO and RO 
Centers present a different pattern of associated 
diseases/medications.  
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Purpose or Objective: Contact X Ray Brachytherapy (CXB) 
was pioneered in France for conservative treatment of rectal 
cancer using the Philips RT 50TM machine. Since 2009 the 
new Papillon 50TM was manufactured. It delivers high dose 
rate (20 Gy/ mn) well targeted dose (30 Gy) into the rectal 
tumor using an endoscopic approach. For T2 T3 CXB is always 
combined with external beam Radiotherapy(EBRT) or with 
chemoraradiotherapy (CRT). Three centers have been 
treating patients in France with such regimen in Lyon-
Villeurbanne, Mâcon and Nice. 
 
Material and Methods: All patients presented 
adenocarcinoma of the distal or middle rectum. Staging used 
Digital examination, endoscopy, MRI and or Endorectal 
ultrasound. CXB dose was 90Gy in 3 fractions (Day 1- 14 -28) 
and EBRT delivered 50 Gy/25 fr/5 weeks usually with 
concurrent capecitabine (800 mg/m2 BID). After clinical 
complete response (cCR) either watch and Wait (W§W) or 
Local excision (LE) was proposed. 
 
Results: Between 2009 and 2014, 44 patients were treated. 
All these patients were either high surgical risk, refusal of 
surgery or referred after MDT approval for such a 
conservative approach Results are shown in Table . 
 
Centre N° pts T2 T3 cCR Loc. Rec. Organ Preserv Surv. 3 years 
Mâcon 14 6 8 10 3 9 75% 
Nice 22 13 9 20 2 21 70% 
Villeurbanne 8 6 2 8 1 7 87% 
Total 44 25 19 89% (38) 13% (6) 83% (37) 77% 
 
Conclusion: The present early results achieved with the 
Papillon 50 machine are at least equivalent to the previous 
one using Philips RT 50. CXB technique is validated in France 
for rectal cancer since 2008 (HAS) and recently in UK (NICE). 
Organ preservation using CXB in frail, elderly patients is a 
well admitted treatment and the ongoing OPERA trial is 
aiming at showing its benefit in operable patients. Gerard JP 
et al. Acta Oncol. 2015 Apr;54(4):545-51. 
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Purpose or Objective: TME surgery, with or without pre-
operative (chemo-)radiotherapy is the standard of care in 
patients with resectable rectal cancer. In patients unfit for 
surgery, radiotherapy alone is often used with palliative 
intent. However, complete response can be achieved when 
high doses are administered. In this study we examined the 
feasibility of external beam radiotherapy (EBRT) followed by 
an endorectal brachytherapy boost in elderly patients, unfit 
for surgery. Primary results, presented at ESTRO 2014, are 
now complemented with response assessment and long-term 
FU at 3 years. 
 
Material and Methods: A dose finding feasibility study was 
performed from 2007 to 2013 in two hospitals in inoperable 
rectal cancer patients. Treatment consisted of EBRT (13x3 
